Abstract
Objective To observe the clinical efficacy of ranibizumab intravitreal injections for the treatment of exudative age-related macular degeneration (AMD). Methods Seventy-one eyes of 60 patients with active exudative AMD in the First Affiliated Hospital of Zhengzhou University from June 2013 to June 2014 were collected. The treatment was performed according to the following schedule: intravitreal injection of 0.5 mg ranibizumab once a month for 3 months. Central macula thickness (CFT) was measured by optical coherence tomography (OCT) after the third injection and further injections were based on the measuring process. The best corrected visual acuity (BCVA), and the fundus situation at the third month and the sixth month after this treatment were analysed. Results The effective rate of this treatment was 91.55%. The differences in BCVA and the CFT between pre-treatment and the third month or the sixth month after this treatment were both statistically significant (P=0.002, P=0.001). Conclusion Ranibizumab intravitreal injections for exudative AMD is an effective and safe method. Key words: Age-related macular degeneration, exudative; Ranibizumab; Intavitreal injection; Efficacy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Chinese Journal of Ocular Trauma and Occupational Eye Disease
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
